Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | CNR2 | P34972 | 16/20 | 0.81 |
| ▸ | CNR1 | P21554 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28225833 | 0.99 | ALDH1A1 (0.80) | ALDH1A1HPGDCNR2CNR1NPC1 | |
| SCHEMBL2804157 | 0.92 | ALDH1A1 (0.68) | ALDH1A1HPGDCNR2CNR1NPC1 | |
| SCHEMBL29677813 | 0.92 | ALDH1A1 (0.68) | ALDH1A1HPGDCNR2CNR1NPC1 | |
| SCHEMBL16098077 | 0.90 | HPGD (1.00) | ALDH1A1HPGDCNR2CNR1NPC1 | |
| SCHEMBL601022 | 0.90 | CNR2 (1.00) | ALDH1A1HPGDCNR2CNR1NPC1 | |
| SCHEMBL28050802 | 0.89 | CNR2 (0.77) | ALDH1A1HPGDCNR2CNR1NPC1 | |
| SCHEMBL28394599 | 0.88 | CNR2 (0.75) | ALDH1A1HPGDCNR2CNR1NPC1 | |
| SCHEMBL28050803 | 0.88 | CNR2 (0.75) | ALDH1A1HPGDCNR2CNR1NPC1 | |
| SCHEMBL28053878 | 0.88 | CNR2 (0.75) | ALDH1A1HPGDCNR2CNR1NPC1 | |
| SCHEMBL28386085 | 0.88 | CNR2 (0.75) | ALDH1A1HPGDCNR2CNR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227332-B2 | T-type calcium channel modulator and uses thereof | UTI LIMITED PARTNERSHIP (CA) | 2019-03-12 | — | — | US | disclosed |
| US-20170233374-A1 | T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2017-08-17 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2016073160-A1 | T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2016-05-12 | — | — | WO | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | ALDH1A1 4037/4885HPGD 1882/4885CNR2 2/4885 |
| US-10227332-B2 | T-type calcium channel modulator and uses thereof | CACNA1E, CACNA1G, TRPC6 | ALDH1A1 3576/4885HPGD 4350/4885CNR2 80/4885 |
| US-20170233374-A1 | T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF | CACNA1E, CACNA1G, TRPC6 | ALDH1A1 3513/4885HPGD 4338/4885CNR2 76/4885 |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | ALDH1A1 4037/4885HPGD 1882/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.